This pre‑formulated research blend combines two synthetic growth hormone secretagogues (GHS): CJC-1295 (without DAC – Drug Affinity Complex) and Ipamorelin (IPA). CJC-1295 (No DAC) is a 30‑amino acid analog of growth hormone‑releasing hormone (GHRH) with enhanced stability but a shorter half‑life compared to its DAC counterpart. Ipamorelin is a pentapeptide that selectively activates the ghrelin receptor (GHS‑R1a) with high specificity and minimal stimulation of cortisol and acylated ghrelin. This 10mg total mass blend (1:1 molar ratio) is supplied as a lyophilized (freeze‑dried) powder in a single glass vial for convenient reconstitution and use in in‑vitro research applications.
| Component | Mass per Vial (approx.) |
| CJC-1295 (No DAC) | 5 mg |
| Ipamorelin (IPA) | 5 mg |
| Total Peptide Mass | 10 mg |
| Parameter | Specification |
| Molar Ratio | 1:1 |
| Purity (each component) | ≥99% (by HPLC) |
- In‑vitro studies of growth hormone secretagogue receptor (GHS‑R1a) activation and downstream signaling.
- Research into the combined effects of GHRH analogs and ghrelin receptor agonists on somatotroph cells.
- Cell culture supplementation (in‑vitro only) for investigating growth hormone release mechanisms.
- Reference blend for analytical method development and comparative studies.
This product is sold strictly for laboratory research purposes only. It is not a drug, medicine, or medical device. Not for human or animal use, consumption, or administration. Not for diagnostic, therapeutic, or clinical applications. Not for use in food or cosmetics. By purchasing, you confirm that you are at least 21 years of age and affiliated with a qualified research institution or laboratory.
